Celecoxib After Tonsillectomy

Tonsillectomy Clinical Trial

Official title:

Celecoxib for Pain Management After Tonsillectomy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02934191
• Other study ID #: 15-011707
• Status: Completed
• Phase: Phase 2
• Start date: June 2016
• Est. completion date: January 31, 2019

Study information

• Verified date: March 2020
• Source: Children's Hospital of Philadelphia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Tonsillectomy is one of the most common pediatric surgical procedures in the United States. Postoperative pain is substantial, with typical regimens employing narcotic derivatives and acetaminophen for 1-2 weeks after surgery. Recent enthusiasm for use of ibuprofen as an alternative has been tempered by equivocal data on its relative safety in regard to risk of postoperative hemorrhage. The primary objective is to evaluate efficacy of celecoxib for pain control after tonsillectomy in children. The secondary objective is to assess safety in regard to postoperative hemorrhage and adverse events.

Description:

This is a randomized, double-blind, placebo-controlled trial. Subjects will take acetaminophen plus either celecoxib or placebo in regular scheduled doses, and will supplement as needed with standard of care analgesic therapy (oxycodone/acetaminophen).

Celecoxib is approved by the FDA for use in children ages 2 and older for treatment of juvenile rheumatoid arthritis (JRA). Celecoxib is on the Children's Hospital of Philadelphia (CHOP) formulary for use in (1) patients >= 2 years old for JRA, (2) patients >= 12 years old and >=40 kg who have increased risk for gastrointestinal (GI) adverse effects or bleeding concerns precluding use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs), and (3) oncology patients with surface area >= 0.4 square meters for anti-angiogenesis. Celecoxib is approved by the FDA for use in adults for treatment of arthritic conditions, acute/ postoperative pain, and primary dysmenorrhea, and has been widely used since its introduction in 1998.

Setting/Participants:Subjects are healthy children aged 3 to 11 years who undergo tonsillectomy with or without adenoidectomy at any Children's Hospital of Philadelphia (CHOP) location. Subjects with coagulation disorders are excluded. Approximately 300 subjects will be enrolled, 150 in each treatment group.

Study Interventions and Measures: Subjects are provided celecoxib or placebo in scheduled doses every 12 hours for 5 days, then continue until they are pain-free, for a maximum of 10 days. Throughout the study, they are allowed to use oxycodone/acetaminophen as needed for additional pain control, following standard clinical care. Acetaminophen is used around the clock for the first 5 days in all subjects. For 14 days following surgery, subjects record pain levels on validated pain scale instruments, quantity of narcotic medication and acetaminophen required, and time to return to normal diet. All Emergency Department and hospital admissions during the 30 postoperative days are recorded, noting incidence of excess pain, dehydration, hemorrhage, and other complications.

Pain control efficacy is assessed by comparing groups for number of days in which narcotic medication was used, and total quantity of rescue pain medication consumed. Rates of hospital readmission and postoperative hemorrhage, and the need for operative control, are also compared between groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 172
• Est. completion date: January 31, 2019
• Est. primary completion date: August 17, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 11 Years

Eligibility

Inclusion Criteria:

1. Males and females age 3 to 11 years inclusive.

2. Scheduled to undergo tonsillectomy (with or without adenoidectomy).

3. Weight =10 kg.

4. Girls = 11 years of age must have a negative urine/serum pregnancy test on the day of surgery and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.

5. Parental/guardian permission (informed consent) and if appropriate, child assent.

Exclusion Criteria:

1. Prior adenotonsillar surgery.

2. Concomitant surgical procedure that adds more than mild additional pain. Note: ear tubes are always permissible.

3. Coagulation disorder, or any other hematologic disorder that affects clotting or results in anemia.

4. Moderate to severe asthma, defined as subjects who either (1) have daily symptoms requiring daily use of short-acting bronchodilators, or (2) had an exacerbation in the last 3 months requiring admission, emergency department (ED) visit, or systemic corticosteroid administration.

5. Any degree of aspirin-sensitive asthma, or any history of asthma exacerbation caused by NSAID use.

6. Severe obstructive sleep apnea, defined as an obstructive apnea-hypopnea index >30 per hour and/or lowest oxygen saturation below 80%

7. Significant chronic pulmonary disease, defined as subjects requiring oxygen therapy, ventilator support, or positive pressure therapy.

8. Significant cardiac disease, defined as any one of the following: cardiovascular disease, structural cardiac anomalies, prior cardiac surgery, or requirement for cardiac anesthesia.

9. Severely obese (weight or body mass index > 95th percentile for age) or underweight (weight <5th percentile for age).

10. History of hepatic or renal disease, or condition that impairs hepatic or renal function.

11. Juvenile rheumatoid arthritis (JRA).

12. History of GI bleeding, or chronic GI condition that would increase risk of bleeding, ulceration, or perforation

13. Hypertension.

14. Craniofacial syndromes.

15. Syndrome or neurologic condition that would hinder accurate assessment of postoperative pain.

16. Inability to feed orally or take oral pain medication.

17. Chronic pain disorders, or otherwise requiring pain medication more than once weekly.

18. Laboratory abnormalities on the preoperative complete blood count (CBC):

• Hemoglobin < 9 gm/dL

• Platelet count < 100,000/mm3

19. Any investigational drug use within 30 days prior to enrollment.

20. Pregnant or lactating females.

21. Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.

22. Hypersensitivity or allergic reactions to celecoxib, aspirin, or other NSAIDs, including asthma flare ups

23. Allergy to sulfonamides or calcium carbonate.

Related Conditions & MeSH terms

• Tonsillectomy

Intervention

Drug:
• Celecoxib
Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally

Other:
• Placebo
Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.

Drug:
• Acetaminophen
Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
• Oxycodone
Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.

Locations

Country	Name	City	State
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Children's Hospital of Philadelphia	Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in Number of Days Requiring Rescue Pain Medication	The number of days on narcotic pain medication following surgery will be compared between the two treatment groups	2 weeks post-operative
Primary	Difference in Amount of Rescue Pain Medication Consumed	The total amount of rescue pain medication consumed in the 2-week postop period will be compared between the two treatment groups.	2 weeks post-operative